Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05704036 · ClinicalTrials.gov registry record · Phase 4
Estrogen Supplementation and Bone Health in Women With CF
A Phase 4 study of Cystic Fibrosis and Hypoestrogenism, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT05704036 is a Phase 4 study of Cystic Fibrosis and Hypoestrogenism that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 75 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05704036, a Phase 4 study of Cystic Fibrosis and Hypoestrogenism, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to learn about the role of estrogen and other hormones in bone development in adolescent and young adult women with cystic fibrosis (CF). The study has two main components, an observational study and a feasibility sub-study. The main questions it aims to answer are: * How do different forms of hormonal contraception (e.g. birth control pill or other progesterone only methods) impact bone health? * Is a study of transdermal estradiol (estrogen skin patches) feasible in this group? * How does transdermal estradiol impact bone health and quality of life? Participants in the observational study will have three study visits (baseline, 6 months, and 12 months). At all visits, participants will have blood drawn and will complete questionnaires. At the baseline and 12 month visits, participants will additionally have x-rays and DXAs (bone density assessment). Between visits, participants will complete brief questionnaires. Researchers will compare various measurements over time to assess the impact of different forms of hormonal contraception. Participants in the feasibility sub-study will apply transdermal estradiol patches once weekly for 12 months, fill out brief quality-of-life surveys in between study visits, and complete blood draws and questionnaires at four study visits (baseline, 3 months, 6 months, and 12 months). The participants will also have x-rays and DXAs performed at the baseline and 12 month visits. Researchers will examine changes in various measurements to determine the impact of transdermal estradiol.
Conditions Studied
Interventions
- DRUG Progesterone
- DRUG Transdermal estrogen
Study Locations (1)
Maryland
- Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-05-02 |
| Est. Completion | 2027-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05704036
The ClinicalTrials.gov registry entry for NCT05704036 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (58% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Progesterone is the first listed.
NCT05704036 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05704036 about?
NCT05704036 is a clinical study titled "Estrogen Supplementation and Bone Health in Women With CF". The goal of this study is to learn about the role of estrogen and other hormones in bone development in adolescent and young adult women with cystic fibrosis (CF). The study has two main components, an observational study and a feasibility sub-study. The main questions it aims to answer are: * How ...
What is the current status of trial NCT05704036?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2023-05-02. Estimated completion is 2027-01.
What conditions does trial NCT05704036 study?
This clinical trial studies the following conditions: Cystic Fibrosis, Hypoestrogenism.
What interventions are being tested in trial NCT05704036?
The interventions under investigation include: Progesterone (DRUG), Transdermal estrogen (DRUG).
Who is sponsoring clinical trial NCT05704036?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05704036 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Markers of Osteoporosis in Cystic Fibrosis
RECRUITING · Phase 4
-
BEGIN Novel ImagiNG Biomarkers
RECRUITING · Phase 4
-
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
RECRUITING · Phase 4
-
Hyperpolarized Imaging for New Treatments
ACTIVE NOT RECRUITING · Phase 4
-
Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis
ACTIVE NOT RECRUITING · Phase 4
-
PR-018: An Open-Label, Safety Extension of Study PR-011
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.